

**FOR IMMEDIATE RELEASE**

**Lee's Present Positive Anfibatide Phase I and II Clinical Data  
showing "a new way to anti-platelet" at ISTH in Amsterdam**

**Hong Kong, July 24, 2013**— Lee's Pharmaceutical Holdings Limited (Main Board Stock Code: 0950: Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the results of phase I study of Anfibatide in healthy human subjects were presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis ("ISTH"), taking place in Amsterdam, the Netherlands on the 2<sup>nd</sup> July 2013.

The abstract titled "First ex vivo and in vivo assessment of Anfibatide, a novel glycoprotein 1b-IV-V complex antagonist, in healthy human volunteers in phase I clinical trial" was selected for oral presentation by the conference and the results was presented by Dr. Benjamin Li, CEO of Lee's Pharmaceutical Holdings Ltd.

The data shows that Anfibatide can bind to approximately 95% of GPIb and inhibit up to 90% of ristocetin specific platelet aggregation without significantly prolonging human bleeding time, activated partial thromboplastin time (APTT), prothrombin time (PT), or thrombin time (TT). The inhibitory effect was reversible in approximately four hours after withdrawal of Anfibatide. There was also no spontaneous bleeding or bleeding from blood collection sites. The study also reveals that Anfibatide did not significantly affect platelet count and no anti-Anfibatide antibodies were detected in the subjects, suggesting that Anfibatide is well-tolerated in healthy individuals. Anfibatide is currently undergone Phase II dose escalating study in China.

**About Anfibatide**

Anfibatide is a new molecular entity discovered and developed by the Group. It is a first-in-class platelet 1b receptors antagonist and is currently undergone phase II clinical study. Animal studies have shown that intravenous injection of Anfibatide effectively abolishes the cyclic flow reduction in canine model of unstable angina with much less prolongation of bleeding time than platelet 2b3a receptors antagonist. Phase I study reveals that Anfibatide is a potent inhibitor of platelet aggregation in healthy volunteer and does not increase the risk of bleeding. Anfibatide represents a novel therapeutic mechanism and may advance the treatment of acute coronary syndrome and percutaneous coronary intervention. It is expected that Anfibatide could have an important role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of thrombosis in patients undergone PTCA and stenting. The Group has obtained patents in US and China for this product.



---

**FOR IMMEDIATE RELEASE**

**About Lee's Pharmaceutical**

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at [www.leespharm.com](http://www.leespharm.com).

**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:*

*Vivian Fung*

*Tel: (852)2314-1282*

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*